Compositions and methods for
The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to bacteria of the genus Bacillus (e.g., Bacillus anthracis ) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising Bacillus anthracis or an immunogenic portion thereof). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications.
1. A method of inducing an immune response to Bacillus anthracis ( B. anthracis ) in a subject comprising intranasally administering an immunogenic composition comprising:
A) a nanoemulsion, wherein the nanoemulsion comprises:
1. oil;
2. water;
3. ethanol;
4. a polysorbate surfactant selected from the group consisting of polyoxyethylene sorbitan monooleate and polyoxyethylene sorbitan monolaurate; and
5. cetylpyridinium chloride (CPC); and
B) recombinant protective antigen (rPA) of B. anthracis to the subject, wherein the administering generates a B. anthracis -specific immune response comprising generation of a serum anthrax lethal toxin (LeTx)-specific neutralizing antibody titer that is at least 10 fold greater than the serum LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
2. The method of claim 1 , wherein said administering comprises contacting the nasal mucosal surface of said subject with said composition.
3. The method of claim 1 , wherein the B. anthracis -specific immune response comprises a systemic IgG response to said rPA of B. anthracis and a mucosal IgA response to said rPA of B. anthracis.
4. The method of claim 1 , wherein said immunogenic composition comprises between 1 and 500 μg of said rPA.
5. The method of claim 1 , wherein said immunogenic composition comprises 5%-20% nanoemulsion solution.
6. The method of claim 1 , wherein said B. anthracis -specific immune response permits said subject to survive a lethal B. anthracis challenge.
7. The method of claim 1 , wherein said B. anthracis -specific immune response prevents said subject from displaying signs or symptoms of B. anthracis infection upon subsequent exposure of said subject to live B. anthracis.
8. The method of claim 1 , wherein said B. anthracis -specific immune response comprises a rPA-specific Th1 type cell mediated immune response comprising at least a 3 fold increased expression of IFN-γ in said subject compared to a control subject not administered said immunogenic composition.
9. The method of claim 1 , wherein said LeTx-specific neutralizing antibody is at least 100 fold greater than the LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
10. The method of claim 1 , said LeTx-specific neutralizing antibody titer is at least 500 fold greater than the LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
11. The method of claim 1 , said LeTx-specific neutralizing antibody titer is at least 1000 fold greater than the LeTx-specific neutralizing antibody titer generated in a control subject administered an equal amount of rPA suspended in saline.
12. The method of claim 1 , wherein said immunogenic composition comprises 20-100 μg of said rPA.
13. The method of claim 1 , wherein said immunogenic composition comprises a 10% nanoemulsion solution.
14. A method of inducing an immune response to Bacillus anthracis ( B. anthracis ) in a subject comprising intranasally administering an immunogenic composition comprising:
A) a nanoemulsion, wherein the nanoemulsion comprises:
1. oil;
2. water;
3. ethanol;
4. a polysorbate surfactant selected from the group consisting of polyoxyethylene sorbitan monooleate and polyoxyethylene sorbitan monolaurate; and
5. cetylpyridinium chloride (CPC); and
B) recombinant protective antigen (rPA) of B. anthracis to the subject, wherein the administering generates a B. anthracis -specific immune response comprising generation of a serum anthrax lethal toxin (LeTx)-specific neutralizing antibody titer that permits said subject to survive a lethal B. anthracis challenge.